E
The startup develops small molecule therapeutics that enhance dermal tissue penetration, enabling targeted treatment of autoimmune diseases with minimal systemic exposure. This approach allows for effective topical and oral administration of inverse agonists, reducing the risks associated with off-target activity and immune suppression.
Encinitas, United States
Updated 2 months ago
Funding
$22.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small molecule therapeutics that enhance dermal tissue penetration, enabling targeted treatment of autoimmune diseases with minimal systemic exposure. This approach allows for effective topical and oral administration of inverse agonists, reducing the risks associated with off-target activity and immune suppression.